Literature DB >> 31787341

A Novel Inside-out Access Approach for Hemodialysis Catheter Placement in Patients With Thoracic Central Venous Occlusion.

Roman Reindl-Schwaighofer1, Vladimir Matoussevitch2, Wolfgang Winnicki3, Egan Kalmykov2, James Gilbert4, Wolfgang Matzek5, Gürkan Sengölge1.   

Abstract

RATIONALE &
OBJECTIVE: Left-sided internal jugular and all subclavian central venous catheters (CVCs) cause thoracic central vein occlusions (TCVOs) more often than right-sided internal jugular catheters. To enable right-sided CVC placement in patients with TCVO, an inside-out access (IOA) approach was established at 3 vascular access centers in Europe involving use of a novel IOA device advanced from the right femoral vein. In the current analysis, we assessed the eligibility and success rate of this IOA approach in a cohort of patients with TCVO requiring a tunneled dialysis catheter. STUDY
DESIGN: Retrospective multicenter observational study. SETTING & PARTICIPANTS: 36 patients with TCVO treated in Vienna, Austria; Oxford, England; or Cologne, Germany, who required hemodialysis access between July 2016 and June 2018. EXPOSURE: Application of the IOA approach to gain vascular access. OUTCOME: The primary end point was the success rate of passing the TCVO to gain dialysis access using the IOA approach. Secondary end points were catheter patency at 3 months and procedure-related complications (early infections, bleeding, hematoma, and pericardial effusions). ANALYTICAL APPROACH: Descriptive statistics to characterize eligibility, success rate, and complications of the IOA approach.
RESULTS: 36 patients with TCVO and history of multiple CVCs and arteriovenous fistulas were referred to the participating centers for vascular access. 32 (89%) patients were eligible for the IOA approach. 39 treatments were performed, with 7 patients undergoing the IOA procedure a second time more than 3 months after initial CVC placement. Dialysis access was established successfully in 38 of 39 (97%) implementations of the IOA procedure. Median intervention time was 43 minutes. No complications occurred. LIMITATIONS: No comparison to other methods to place CVCs and the observational study design.
CONCLUSIONS: The IOA approach is a promising method to enable rapid access to the right jugular vein in the setting of pre-existing TCVO. Additional experience is needed to understand the generalizability of these observations.
Copyright © 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CVC placement; Hemodialysis; catheter patency; central venous catheter (CVC); dialysis catheter; end-stage renal disease (ESRD); insertion site; renal replacement therapy (RRT); sharp recanalization; thoracic central vein occlusion (TCVO); vascular access

Mesh:

Year:  2019        PMID: 31787341     DOI: 10.1053/j.ajkd.2019.08.024

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  3 in total

1.  Efficacy and safety associated with the use of the Surfacer® Inside-Out® Access Catheter System: Results from a prospective, multicenter Food and Drug Administration-approved Investigational Device Exemption study.

Authors:  Mahmood K Razavi; Eric K Peden; Ehab Sorial; John R Ross; John E Aruny; Timothy A Pflederer; Haimanot Wasse; Ziv J Haskal
Journal:  J Vasc Access       Date:  2020-06-27       Impact factor: 2.283

2.  Effect of the Kanghuier Transparent Hydrocolloid Dressing in Preventing Central Venous Catheter Infection and Phlebitis after Cardiac Surgery.

Authors:  Xiaoling Han; Jiayi Li; Ping Zeng; Chunfeng Luo; Dongmei Zhou
Journal:  Comput Math Methods Med       Date:  2022-04-01       Impact factor: 2.238

3.  The efficacy and safety of blunt impingement followed by a sharp recanalization technique in hemodialysis patients with refractory central vein occlusion: a single-center experience.

Authors:  Ji-Bo Sun; Qiu-Yan Zhao; Stephen Salerno; Xi Shen; Yi Li; Ping Fu; Tian-Lei Cui
Journal:  Ann Transl Med       Date:  2022-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.